Environmental or self-antigens and homotypic interactions induce BCR and Toll-like receptor (TLR) signaling, amplifying the response of CLL cells to other signals through the microenvironment and escalating the activation of anti-apoptotic and proliferation pathways. Duvelisib was the 2nd PI3K inhibitor accredited because of the FDA, also based on a phase https://carolineg791myb4.tkzblog.com/profile